Physician profile
Peter Schwarz
NPI 1700867165
$14,391.93
in general payments reported to CMS, 2019-2025
40 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,060 · 2020: $1,625 · 2021: $1,848 · 2022: $2,367 · 2023: $1,639 · 2024: $1,784 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,462 · Education: $29.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,462.26 |
| Education | $29.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,293.59 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,485.40 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,354.41 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,034.13 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $909.55 | 2019-2025 | |
| Celgene Corporation | $680.80 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $657.20 | 2019-2024 | Rebyota, Cimzia |
| Gilead Sciences, INC. | $362.80 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $297.78 | 2021-2023 | Dificid |
| Ardelyx, INC. | $247.61 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $214.48 | 2019-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $187.97 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $173.59 | 2024-2025 | Zenpep |
| Allergan, INC. | $146.83 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $132.28 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Schwarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.